Literature DB >> 33384965

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer.

Seth R Blacksburg1, Donald B Fuller2, Jonathan A Haas1.   

Abstract

Entities:  

Keywords:  Stereotactic Body Radiation Therapy; prostate; prostate cancer; radiotherapy; stereotactic

Year:  2020        PMID： 33384965      PMCID： PMC7770153          DOI： 10.3389/fonc.2020.627686

Source DB:  PubMed          Journal:  Front Oncol        ISSN： 2234-943X            Impact factor:   6.244


× No keyword cloud information.
  57 in total

Review 1.  Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee.

Authors:  Mark K Buyyounouski; Robert A Price; Eleanor E R Harris; Robert Miller; Wolfgang Tomé; Tracey Schefter; E Ishmael Parsai; Andre A Konski; Paul E Wallner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04       Impact factor: 7.038

2.  Intrafraction prostate translations and rotations during hypofractionated robotic radiation surgery: dosimetric impact of correction strategies and margins.

Authors:  Steven van de Water; Lorella Valli; Shafak Aluwini; Nico Lanconelli; Ben Heijmen; Mischa Hoogeman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

3.  A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.

Authors:  John V Hegde; Sean P Collins; Donald B Fuller; Christopher R King; D Jeffrey Demanes; Pin-Chieh Wang; Patrick A Kupelian; Michael L Steinberg; Mitchell Kamrava
Journal:  Am J Clin Oncol       Date:  2018-05       Impact factor: 2.339

4.  Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.

Authors:  Chad G Rusthoven; Bernard L Jones; Thomas W Flaig; E David Crawford; Matthew Koshy; David J Sher; Usama Mahmood; Ronald C Chen; Brian F Chapin; Brian D Kavanagh; Thomas J Pugh
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

5.  Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.

Authors:  Rupesh Kotecha; Toufik Djemil; Rahul D Tendulkar; Chandana A Reddy; Richard A Thousand; Andrew Vassil; Mark Stovsky; Ryan K Berglund; Eric A Klein; Kevin L Stephans
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-06       Impact factor: 7.038

6.  Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.

Authors:  Brock R Baker; Ramsankar Basak; Jahan J Mohiuddin; Ronald C Chen
Journal:  Cancer       Date:  2016-05-12       Impact factor: 6.860

7.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

8.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Authors:  Stephen H Culp; Paul F Schellhammer; Michael B Williams
Journal:  Eur Urol       Date:  2013-11-20       Impact factor: 20.096

Review 9.  Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.

Authors:  Robert Meier
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

10.  Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.

Authors:  Sarah Burdett; Liselotte M Boevé; Fiona C Ingleby; David J Fisher; Larysa H Rydzewska; Claire L Vale; George van Andel; Noel W Clarke; Maarten C Hulshof; Nicholas D James; Christopher C Parker; Mahesh K Parmar; Christopher J Sweeney; Matthew R Sydes; Bertrand Tombal; Paul C Verhagen; Jayne F Tierney
Journal:  Eur Urol       Date:  2019-02-28       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.